Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.

@article{Li2012ExploringTS,
  title={Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.},
  author={Yan Li and W. Wu and H. M. Ren and Jinghui Wang and Shuwei Zhang and Guohui Li and Ling Yang},
  journal={Journal of molecular graphics & modelling},
  year={2012},
  volume={38},
  pages={
          112-22
        }
}
Phosphodiesterase type 5 (PDE5) inhibitors are clinically indicated for the treatment of erectile dysfunction, pulmonary hypertension and various other diseases. In this work, both ligand- and receptor-based three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques on 122 pyrazinone derivatives as PDE inhibitors. The resultant… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

3 DQSAR of aminosubstituted pyrido [ 3 , 2 B ] pyrazinones as PDE5 inhibitors

  • R. Saha O. Tanwar, M. M. Alam, M. Akhtar
  • Medicinal Chemistry Research
  • 2012

3 DQSAR studies on sildenafil analogues , selective phosphodiesterase 5 inhibitors

  • K. M. Thai J. Yoo, D. K. Kim, J. Y. Lee, H. J. Park
  • Bioorganic & Medicinal Chemistry Letters
  • 2012

Combined 3 DQSAR , molecular docking and molecular dynamics study on derivatives of peptide epoxyketone and tyropeptinboronic acid as inhibitors against the  5 subunit of human 20 S proteasome

  • H. Zhang, Z. Xiao, F. Wang, X. Wang, Y. Wang
  • International Journal of Molecular Science
  • 2011

Docking and 3 DQSAR studies on isatin sulfonamide analogues as caspase - 3 inhibitors

  • R. H. Mach, D. E. Reichert
  • QSAR Combinatorial Science
  • 2009